Patent · US Active

Analogs of dextromethorphan with balanced receptor activities

US11535596B2 · kind B2 · utility

0Cited by

1References

16Claims

0Family size

Assignee

Center for Neurologic Study · US

Inventors

Richard A. Smith · Cameron Park, US
Darryl Rideout · Del Mar, US
Kathleen Myers · Oceanside, US
Andrew M. Kawasaki · San Diego, US

Key dates

Filing date	Aug 30, 2021
Grant date	Dec 27, 2022
Priority date	—
Expiry date	Aug 30, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D405/06
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Substituted analogs of dextromethorphan (DM) are disclosed, which are shown to have substantial binding affinity at both NMDA and sigma-1 receptors, and which are degraded by human liver enzymes more slowly than dextromethorphan. The analogs are useful as alternatives to dextromethorphan, and can provide the same benefits without requiring co-administration of a cytochrome P-450 enzyme inhibitor.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.